This site is intended for US audiences only. If you are a resident of the European Union, please click here for the EU version of our site.
PNH: Diagnosis and Testing
Evaluate High-Risk Patient Populations for PNH1
Symptomatology common to many diseases, as well as the rarity of PNH, may delay diagnosis. But because the disease can result in serious clinical sequelae when chronic hemolysis is not controlled, early diagnosis is crucial.
PNH Consensus Guidelines and the International PNH Interest Group recommend continued monitoring of patient populations at higher risk for PNH. Populations include: Coombs-negative hemolytic anemia, hemoglobinuria, aplastic anemia, refractory anemia-myelodysplastic syndrome, unexplained cytopenias, and unexplained thrombosis.1,2
Classical PNH can be confused with autoimmune hemolytic anemia or congenital hemolytic anemias.3 PNH symptoms can change over time, and measuring lactate dehydrogenase (LDH) activity will provide a more complete clinical picture of PNH.4-6 In patients at high risk for PNH flow cytometry should be performed.
Detection of PNH clones by flow cytometry, via peripheral blood, is the gold standard diagnostic test for PNH. Flow cytometry provides the most consistent and sensitive method of testing for PNH.2